Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

824 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Doglioni C, Villa E. Reni M, et al. Among authors: doglioni c. Cancer Chemother Pharmacol. 2012 Jan;69(1):115-23. doi: 10.1007/s00280-011-1680-2. Epub 2011 May 28. Cancer Chemother Pharmacol. 2012. PMID: 21626049 Clinical Trial.
The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma.
Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Albarello L, Doglioni C, Anselmo A, Doni A, Bianchi P, Laghi L, Malesci A, Cervo L, Malosio M, Reni M, Zerbi A, Di Carlo V, Mantovani A, Allavena P. Marchesi F, et al. Among authors: doglioni c. Cancer Res. 2008 Nov 1;68(21):9060-9. doi: 10.1158/0008-5472.CAN-08-1810. Cancer Res. 2008. PMID: 18974152
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients.
Balzano G, Dugnani E, Pasquale V, Capretti G, Radaelli MG, Garito T, Stratta G, Nini A, Di Fenza R, Castoldi R, Staudacher C, Reni M, Scavini M, Doglioni C, Piemonti L. Balzano G, et al. Among authors: doglioni c. Acta Diabetol. 2014 Oct;51(5):801-11. doi: 10.1007/s00592-014-0614-y. Epub 2014 Jun 29. Acta Diabetol. 2014. PMID: 24974302
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, Liberati D, Pasquale V, Scavini M, Maggiora P, Sordi V, Lampasona V, Ceraulo D, Di Terlizzi G, Doglioni C, Falconi M, Piemonti L. Reni M, et al. Among authors: doglioni c. Clin Cancer Res. 2016 Mar 1;22(5):1076-85. doi: 10.1158/1078-0432.CCR-15-1722. Epub 2015 Oct 12. Clin Cancer Res. 2016. PMID: 26459175 Clinical Trial.
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.
Belli C, Piemonti L, D'Incalci M, Zucchetti M, Porcu L, Cappio S, Doglioni C, Allavena P, Ceraulo D, Maggiora P, Dugnani E, Cangi MG, Garassini G, Reni M. Belli C, et al. Among authors: doglioni c. Cancer Chemother Pharmacol. 2016 Mar;77(3):477-84. doi: 10.1007/s00280-015-2932-3. Epub 2015 Dec 14. Cancer Chemother Pharmacol. 2016. PMID: 26666646 Clinical Trial.
824 results